Czy tylko inhibitory konwertazy i sartany hamują układ renina-angiotensyna? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2009
Słowa kluczowe:
układ renina-angiotensyna, enzym konwertujący, angiotensyna 1-7, aminopeptydaza A
##plugins.themes.bootstrap3.article.main##
Abstrakt
Wiele dowodów wskazuje na udział układu renina-angiotensyna w patogenezie chorób układu sercowo-naczyniowego. Oprócz enzymu konwertującego i angiotensyn I i II poznano jego nowe elementy: enzym konwertujący 2, angiotensynę 1-7 czy aminopeptydazę A. W ciągu ostatnich lat wprowadzono do leczenia nowe leki hamujące układ renina-angiotensyna. Należy wymienić spośród nich: eplerenon – antagonistę aldosteronu, i aliskiren – bezpośredni inhibitor reniny. Obecnie badane są nowe substancje mogące na różnych etapach hamować aktywność tego układu.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Lewandowski , J., & Jędrusik , P. (2009). Czy tylko inhibitory konwertazy i sartany hamują układ renina-angiotensyna? . Kardiologia W Praktyce, 3(4), 163-168. Pobrano z https://www.journalsmededu.pl/index.php/kwp/article/view/1648
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. NEJM 2008, 358: 1547-1559.
2. Rump L.Ch.: Secondary rise of albuminuria under AT1-receptor blockade – what is the potential role of aldosterone escape? Nephrol. Dial. Transplant. 2007, 22: 5.
3. Albert N.M., Yancy C.W., Liang L. et al.: Use of aldosterone antagonists in heart failure. JAMA 2009, 302: 1658-1665.
4. Dzau V.J.: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988, 77: 1-3.
5. Dzau V.J., Sasamura H., Hein L.: Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J. Hypertens. 1993, 11(suppl.): S13-18.
6. Timmermans P.B., Smith R.D.: Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur. Heart J. 1994, 15(suppl D): 79-87. 7. Weir M.R., Dzau V.J.: The Renin-Angiotensin-Aldosterone System: A Specific Target for Hypertension Management AJH 1999, 12: 205S-213S.
7. Campbell D.J.: Critical review of prorenin and (pro)renin receptor research. Hypertension 2008 [online: DOI: 10.1161/HYPERTENSIONAHA.108.110924].
8. Reudelhuber T.L.: A place in our hearts for the lowly angiotensin 1-7 peptide? Hypertension 2006, 47: 811-815.
9. Chappell M.C.: Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin- (1-7)-Mas receptor axis: more than regulation of blood pressure? Hypertension 2007, 50: 596-599.
10. Diez-Freire C., Vazquez J., Correa de Adjounian M.F. et al.: ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol. Genomics. 2006, 27: 12-19.
11. Hernandez Prada J., Ferreira A.J., Katovich M.J.: Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive Agents. Hypertension. 2008, 51: 1312-1317.
12. Benter I.F., Yousif M.H.M., Cojocel C. et al.: Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2007, 292: H666-H672.
13. Ferreira A.J., Raizada M.K.: Aminopeptidase A Could It Be a Novel Target for Neurogenic Hypertension? Hypertension 2008, 51: 1273-1274.
14. Bodineau L., Frugie`re A., Marc Y., et al.: Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension 2008; 51: 1318-1325.
15. Weinberger M.H., Roniker B., Krause S.L., Weiss R.J.: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 2002, 15: 709-716.
16. Epstein M., Alexander J.C., Roniker B.: Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension. Hypertension 1999, 33: 1075.
17. Pitt B., Reichek N., Metscher B. et al.: Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy for essential hypertension and left ventricular hypertrophy: The 4E Study. Circulation 2003, 108: 1831-1838.
18. Pitt B., Remme W., Zannad F. et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348: 1309-1321.
19. Wood J.M., Cumin F., Maibaum J.: Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol. Ther. 1994, 61: 325-344.
20. Rajagopalan S., Duquaine D., King S. et al.: Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis. Circulation 2002, 105: 2212-2216.
21. Brown M.J.: Aliskiren. Circulation 2008, 118: 773-784.
22. Gradman A.H., Kad R.: Renin Inhibition in Hypertension. JACC 2008, 51(5): 519-28.
23. Andersen K., Weinberger M.H., Egan B. et al.: Aliskiren-based therapy lowers blood pressure more effectively than ramipril-based therapy in patients with hypertension: a 6-month, randomized, double blind trial. J. Am. Coll. Cardiol. 2007, 49 (Suppl. A): A371.
24. Stanton A., Jensen C., Nussberger J., O’Brien E.: Blood pressure lowering in essential hypertension with oral renin inhibitor, aliskiren. Hypertension 2003, 42: 1137-1143.
25. Oparil S., Yarows S.A., Patel S. et al.: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized double-blind trial. Lancet 2007, 370: 221-9.
26. Villamil A., Chrysant S.G., Calhoun D. et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens. 2007, 25: 217-26.
27. Uresin Y., Taylor A.A., Kilo C. et al.: Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin Angiotensin Aldosterone Syst. 2007, 8: 190-198.
28. McMurray J.J.V., Pitt B., Latini R. et al.: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 2008, 1: 17-24.
29. Parving H.-H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 2008, 358: 2433–2446.
30. Solomon S., Appelbaum E., Manning W.J. et al.: The Aliskiren Left Ventricular Assessment of Hypertrophy (ALLAY) Trial. [online: http:// www.medicalnewstoday. com/ articles/102328.php] .
31. Reudelhuber T.L.: A Place in Our Hearts for the Lowly Angiotensin 1-7 Peptide? Hypertension 2006, 47: 811-815.
2. Rump L.Ch.: Secondary rise of albuminuria under AT1-receptor blockade – what is the potential role of aldosterone escape? Nephrol. Dial. Transplant. 2007, 22: 5.
3. Albert N.M., Yancy C.W., Liang L. et al.: Use of aldosterone antagonists in heart failure. JAMA 2009, 302: 1658-1665.
4. Dzau V.J.: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988, 77: 1-3.
5. Dzau V.J., Sasamura H., Hein L.: Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J. Hypertens. 1993, 11(suppl.): S13-18.
6. Timmermans P.B., Smith R.D.: Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur. Heart J. 1994, 15(suppl D): 79-87. 7. Weir M.R., Dzau V.J.: The Renin-Angiotensin-Aldosterone System: A Specific Target for Hypertension Management AJH 1999, 12: 205S-213S.
7. Campbell D.J.: Critical review of prorenin and (pro)renin receptor research. Hypertension 2008 [online: DOI: 10.1161/HYPERTENSIONAHA.108.110924].
8. Reudelhuber T.L.: A place in our hearts for the lowly angiotensin 1-7 peptide? Hypertension 2006, 47: 811-815.
9. Chappell M.C.: Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin- (1-7)-Mas receptor axis: more than regulation of blood pressure? Hypertension 2007, 50: 596-599.
10. Diez-Freire C., Vazquez J., Correa de Adjounian M.F. et al.: ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol. Genomics. 2006, 27: 12-19.
11. Hernandez Prada J., Ferreira A.J., Katovich M.J.: Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive Agents. Hypertension. 2008, 51: 1312-1317.
12. Benter I.F., Yousif M.H.M., Cojocel C. et al.: Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2007, 292: H666-H672.
13. Ferreira A.J., Raizada M.K.: Aminopeptidase A Could It Be a Novel Target for Neurogenic Hypertension? Hypertension 2008, 51: 1273-1274.
14. Bodineau L., Frugie`re A., Marc Y., et al.: Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension 2008; 51: 1318-1325.
15. Weinberger M.H., Roniker B., Krause S.L., Weiss R.J.: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 2002, 15: 709-716.
16. Epstein M., Alexander J.C., Roniker B.: Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension. Hypertension 1999, 33: 1075.
17. Pitt B., Reichek N., Metscher B. et al.: Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy for essential hypertension and left ventricular hypertrophy: The 4E Study. Circulation 2003, 108: 1831-1838.
18. Pitt B., Remme W., Zannad F. et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348: 1309-1321.
19. Wood J.M., Cumin F., Maibaum J.: Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol. Ther. 1994, 61: 325-344.
20. Rajagopalan S., Duquaine D., King S. et al.: Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis. Circulation 2002, 105: 2212-2216.
21. Brown M.J.: Aliskiren. Circulation 2008, 118: 773-784.
22. Gradman A.H., Kad R.: Renin Inhibition in Hypertension. JACC 2008, 51(5): 519-28.
23. Andersen K., Weinberger M.H., Egan B. et al.: Aliskiren-based therapy lowers blood pressure more effectively than ramipril-based therapy in patients with hypertension: a 6-month, randomized, double blind trial. J. Am. Coll. Cardiol. 2007, 49 (Suppl. A): A371.
24. Stanton A., Jensen C., Nussberger J., O’Brien E.: Blood pressure lowering in essential hypertension with oral renin inhibitor, aliskiren. Hypertension 2003, 42: 1137-1143.
25. Oparil S., Yarows S.A., Patel S. et al.: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized double-blind trial. Lancet 2007, 370: 221-9.
26. Villamil A., Chrysant S.G., Calhoun D. et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens. 2007, 25: 217-26.
27. Uresin Y., Taylor A.A., Kilo C. et al.: Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin Angiotensin Aldosterone Syst. 2007, 8: 190-198.
28. McMurray J.J.V., Pitt B., Latini R. et al.: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 2008, 1: 17-24.
29. Parving H.-H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 2008, 358: 2433–2446.
30. Solomon S., Appelbaum E., Manning W.J. et al.: The Aliskiren Left Ventricular Assessment of Hypertrophy (ALLAY) Trial. [online: http:// www.medicalnewstoday. com/ articles/102328.php] .
31. Reudelhuber T.L.: A Place in Our Hearts for the Lowly Angiotensin 1-7 Peptide? Hypertension 2006, 47: 811-815.